| Name | Title | Contact Details |
|---|
InnovaPrep is engaged in product development, manufacturing, sales, service, and related out-licensing of a collection of novel technologies enabling rapid detection of biological particles and pathogens. Our core business is biological sample collection, concentration and preparation. The company has commercialized a collection of market-disruptive platform technologies for rapid, automated concentration of biological particles. InnovaPrep`s 35 pending and awarded patents apply to highly efficient collection, recovery, and concentration of biological particles from air, surfaces, and liquids. Our elution process underlies many of these patents and enables recovery of particles from filters, membranes, surfaces, and objects. The primary utility for these technologies is to greatly improve the way biological samples, especially those containing pathogenic organisms, are collected and prepared for analysis beyond the state-of-the-art. These technologies fill a critical void that currently severely limits application of the most advanced biological detection systems to the billions of microbiological tests performed annually. Markets served: Biodefense, food safety, water safety, biopharma, clinical research, animal health, environmental monitoring and others.
Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amylin Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
ProZyme is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MiMedx is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products with over 40 scientific and clinical publications contained in our Compendium, six completed and published Randomized Controlled Trials (RCTs), and 30 ongoing clinical studies. MiMedx has over 45 placental tissue issued and allowed patents on our products and technologies, with over 90 pending applications. We have continued to demonstrate this leadership by publishing a Primer to educate the medical community on the regenerative aspects of amniotic membrane allografts. MiMedx has supplied over 1 million placental tissue-based allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.